title: Expression of urokinase plasminogen activator and plasminogen activator             inhibitor type-1 in ovarian cancer and its clinical significance.
abstract: The urokinase plasminogen activator system, which consists of urokinase             plasminogen activator (uPA), plasminogen activator inhibitor type-1 (PAI-1) and             urokinase plasminogen activator receptor (uPAR), plays an important role in tumor             invasion and metastasis, and it may be a potential diagnostic biomarker and therapeutic             target in cancer. It has been found that the expression of uPA and PAI-1 in ovarian             cancer is related to clinical pathologies, while their effects on the biological             behavior of tumor cells and their clinical significance are still unknown. In             this study, 100 tissue samples (60 samples from malignant tumors, 20 from benign             tumors and 20 from controls) and 147 blood samples (49 samples each from patients             with malignant tumors, benign tumors and control group, respectively) were analyzed.             The positive expression levels of uPA and PAI-1 in the malignant tumor samples             and their serum concentrations in the malignant group were all significantly higher             than these levels in the benign tumors and controls. In addition, the levels in             patients with poorly differentiated and stage III-IV cancers, cancers with metastases             as well as residual tumors >2 cm after surgery, were all obviously increased,             consistent with their concentrations in serum. The Cox model analysis showed that             expression of uPA at the transcription level had significant associations with             prognosis. In addition, uPA greatly enhanced the abilities of cell invasion, migration             and adhesion through its overexpression in SKOV3 cells. Collectively, our results             showed that uPA and PAI-1 play important roles in ovarian cancer development;             therefore, their expression in tissues and their concentrations in serum would             greatly assist the diagnosis and prediction of the prognosis in ovarian cancer.
authors.affiliation: Department of Gynecologic Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi 530021, PR China.
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.forename: Dan
authors.initials: D
authors.lastname: Ling
authors.forename: Jie
authors.initials: J
authors.lastname: Tan
authors.forename: Jieqing
authors.initials: J
authors.lastname: Zhang
authors.forename: Li
authors.initials: L
authors.lastname: Li
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood* / Q000378:metabolism; D016022:Case-Control Studies; D002448:Cell Adhesion; D059447:Cell Cycle Checkpoints; D045744:Cell Line, Tumor; D002465:Cell Movement; D049109:Cell Proliferation; D018282:Cystadenocarcinoma, Mucinous / Q000378:metabolism* / Q000556:secondary / Q000601:surgery; D018284:Cystadenocarcinoma, Serous / Q000378:metabolism* / Q000556:secondary / Q000601:surgery; D018291:Cystadenoma, Mucinous / Q000378:metabolism; D018293:Cystadenoma, Serous / Q000378:metabolism; D005260:Female; D015870:Gene Expression; D005822:Genetic Vectors; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D018365:Neoplasm, Residual; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000473:pathology* / Q000628:therapy; D010053:Ovary / Q000378:metabolism; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood* / Q000378:metabolism; D011379:Prognosis; D016016:Proportional Hazards Models; D012333:RNA, Messenger / Q000378:metabolism; D014162:Transfection; D014568:Urokinase-Type Plasminogen Activator / Q000097:blood* / Q000235:genetics / Q000378:metabolism
chemical_list: D014408:Biomarkers, Tumor; D017395:Plasminogen Activator Inhibitor 1; D012333:RNA, Messenger; D014568:Urokinase-Type Plasminogen Activator